

Barostim™ patient selection

Indications

- NYHA Class III or Class II (who had a recent history of Class III) despite treatment with guideline-directed medical therapies (medications and devices)*
- LVEF \leq 35%
- NT-proBNP < 1,600 pg/mL

Exclusions

- Bilateral carotid bifurcations above mandible level
- Baroreflex failure or autonomic neuropathy
- Uncontrolled, symptomatic cardiac bradyarrhythmias
- > 50% carotid atherosclerosis
- Ulcerative plaques in the carotid artery
- Known allergy to silicone or titanium

*Guideline directed medical therapy (GDMT) according to AHA/ACC/ESC guidelines


CVRx[®]
Outsmart the heart

CVRx, Inc.
9201 West Broadway Avenue, Suite 650
Minneapolis, MN 55445 USA
P 763-416-2840 | F 763-416-2841
cvr.com

950359-001 Rev B

CAUTION: Federal law restricts this device to sale by or on the order of a physician. See System Reference Guide 900133-001 for a complete instruction for use and a description of indications, contraindications, warnings, precautions and adverse events. For a list of all potential benefits and risks go to www.cvr.com/benefit-risk-analysis. CVRx, Barostim, NEO, NEO2, BAT, Barostim NEO, Barostim NEO2, BATwire, Outsmart the heart and Barohub are all trademarks of CVRx, Inc. For a list of applicable patents, see www.cvr.com/patent-marking. ©2024 CVRx, Inc. All rights reserved.

Instructions for Use 900133-001 available at www.cvr.com/ifu





Barostim™
Outsmart the heart